• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

    2/14/22 5:07:14 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    SC 13G/A 1 tm226094d22_sc13ga.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    Avita Medical, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

     

    (Title of Class of Securities)

     

    05380C102

     

    (CUSIP Number)

     

    December 31, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 05380C102

     

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨ 

    (b) ¨

    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    Delaware

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    672,411 (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    672,411 (1)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    672,411 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    2.7%(2)

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

           

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s Common Stock (“Common Stock”) is comprised of 672,411 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on 24,925,118 shares of Common Stock outstanding as of November 5, 2021, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 8, 2021 (the “Form 10-Q”).

     

     

     

     

     

    CUSIP No. 05380C102

     

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3 SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    672,411 (3)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    672,411 (3)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    672,411 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    2.7%(4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

           

     

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 672,411 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on 24,925,118 shares of Common Stock outstanding as of November 5, 2021, as reported by the Issuer in the Form 10-Q.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    AVITA Medical, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    28159 Avenue Stanford, Suite 220

    Valencia, California 91355

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value

     

    (e)CUSIP Number

     

    05380C102

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

     

     

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 672,411 *
    Jeremy C. Green – 672,411 *

     

    (b)Percent of class:

     

    Redmile Group, LLC – 2.7%**
    Jeremy C. Green – 2.7%**

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    672,411 *

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    672,411*

     

     

     

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    672,411*

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    672,411*

     

    *Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of 672,411 shares of Common Stock owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    **Percentage based on 24,925,118 shares of Common Stock outstanding as of November 5, 2021, as reported by the Issuer in the Form 10-Q.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9.Notice of Dissolution of Group.

     

    N/A

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2022

     

      Redmile Group, LLC  
         
      By:   /s/ Jeremy C. Green
          Name: Jeremy C. Green
          Title: Managing Member
           
          /s/ Jeremy C. Green
          Jeremy C. Green  

     

     

     

    Get the next $RCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Financials

    Live finance-specific insights

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business Updates Commercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023Gross profit margin of 87.6%On December 19, 2024, the FDA granted 510(k) clearance for Cohealyx™, an AVITA Medical-branded collagen-based dermal matrixOn December 23, 2024, the FDA approved RECELL GO® miniOn February 13, 2025, amended the credit

      2/13/25 4:01:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avita Medical Inc.

      10-Q - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:15:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVITA Medical, Inc. (0001762303) (Filer)

      5/8/25 4:05:17 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Avita Medical Inc.

      DEF 14A - AVITA Medical, Inc. (0001762303) (Filer)

      4/22/25 4:30:18 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Avita Medical with a new price target

      D. Boral Capital initiated coverage of Avita Medical with a rating of Buy and set a new price target of $25.00

      12/24/24 7:10:27 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Avita Medical downgraded by BTIG Research

      BTIG Research downgraded Avita Medical from Buy to Neutral

      4/11/24 7:58:22 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Avita Medical with a new price target

      Cantor Fitzgerald initiated coverage of Avita Medical with a rating of Overweight and set a new price target of $23.00

      6/27/23 7:26:40 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer

      VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public

      6/15/23 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical Appoints New Non-Executive Member to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023. Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His extensive experience in operations and financial management spans across early stage, high growth, and mature companies. He

      3/23/23 4:30:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      2/13/24 4:58:57 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avita Medical Inc.

      SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

      1/26/24 4:23:41 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

      SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

      2/9/23 11:07:47 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcnamara Robert bought $91,300 worth of shares (11,000 units at $8.30), increasing direct ownership by 24% to 56,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      3/10/25 4:30:06 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • Director Mcnamara Robert bought $100,900 worth of shares (10,000 units at $10.09), increasing direct ownership by 28% to 45,749 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:19 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • CFO O'Toole David D bought $9,900 worth of shares (1,000 units at $9.90), increasing direct ownership by 4% to 25,734 units (SEC Form 4)

      4 - AVITA Medical, Inc. (0001762303) (Issuer)

      2/20/25 4:30:08 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Reports First Quarter 2025 Financial Results

      VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights and Recent Developments Commercial revenue of $18.5 million, an increase of approximately 67% compared to the same period in 2024Gross profit margin of 84.7%In February, launched RECELL GO mini™, designed to treat smaller wounds, targeting U.S. trauma centers treating a high volume of small-area woundsOn April 1, initiated nationwide launch of Cohealyx™, an AVITA Medical-branded collagen-based d

      5/8/25 4:03:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025

      VALENCIA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will host its inaugural Acute Wound Care Showcase 2025 on Tuesday, May 13, 2025, via webcast at 11:00 a.m. Pacific Time. The event will feature presentations from Jim Corbett, Chief Executive Officer, and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs. The Acute Wound Care Showcase will provide an overview of AVITA Medical's comprehensive approach to acute wound care. Attendees joining the webcast will gain insights into the company's product portfolio, includi

      4/24/25 9:00:00 AM ET
      $RCEL
      Medical/Dental Instruments
      Health Care
    • AVITA Medical to Announce First Quarter 2025 Financial Results

      VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by

      4/17/25 4:05:00 PM ET
      $RCEL
      Medical/Dental Instruments
      Health Care